Inhibition of Receptor for Advanced Glycation End Products as New Promising Strategy Treatment in Diabetic Retinopathy

Authors

  • Irsan Saleh Department of Pharmacology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
  • Ziske Maritska Department of Biology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
  • Nita Parisa Department of Pharmacology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
  • Rachmat Hidayat Department of Biology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2019.759

Keywords:

RAGEs, diabetic retinopathy, HbA1c, neural growth factor, glial acidic fibrillary protein

Abstract

BACKGROUND: Extensive intracellular and extracellular formation of advanced glycation end-products (AGEs) is considered a causative factor for vascular injury triggered by hyperglycemia in diabetes. The hyperglycemia will cause accumulation of AGEs, damage to pericytes, nerve growth factor (NGF), glial acid fibrillary protein (GFAP) and increase in vascular endothelial growth factor (VEGF).

AIM: This study aimed to assess the efficacy of RAGE inhibition in suppressing the development and progression of diabetic retinopathy through modulation of the inflammatory pathway involving NGF, GFAP, and VEGF.

METHODS: The design was in vivo experimental study. Thirty white rats were induced with Alloxan monohydrate. Rats were divided into 5 groups, normal, negative control, groups with an anti-RAGE dose of 1 μg/uL, the dose of 10 μg/uL and 100 μg/uL. After 4 weeks of treatment, HbA1c, NGF, and GFAP levels were measured using ELISA. Quantification of VEGF expression was done using the ImageJ® application. Data was expressed with mean ± SD. Independent T-test with ANOVA and Tukey's post hoc was done.

RESULTS: RAGE inhibitors yielded a significant decrease in blood glucose and HbA1c levels. VEGF and RAGE expression were reduced in anti-RAGE groups in various doses. Inhibition of RAGE reduced the damage of retinal pericytes, by reducing GFAP and increasing NGF, and reduced the formation of new blood vessels, by decreasing VEGF expression, in diabetic retinopathy.

CONCLUSION: Inhibition of receptor for advanced glycation end-products (RAGE) was effective in suppressing the development and progression of diabetic retinopathy.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

Published

2019-10-14

How to Cite

1.
Saleh I, Maritska Z, Parisa N, Hidayat R. Inhibition of Receptor for Advanced Glycation End Products as New Promising Strategy Treatment in Diabetic Retinopathy. Open Access Maced J Med Sci [Internet]. 2019 Oct. 14 [cited 2022 Dec. 6];7(23):3921-4. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2019.759

Issue

Section

A - Basic Science

Most read articles by the same author(s)

1 2 > >>